INC Research/inVentiv Health Becomes Syneos Health™
The word Syneos (pronounced SIN-ee-ohs) communicates the value of synchronizing clinical and commercial capabilities to accelerate customer performance.
The name is also derived from “neo,” signaling a new approach to problem-solving and a new biopharmaceutical solutions category for the healthcare workforce. The company logo communicates the seamless integration of multidisciplinary services, and the color palette is a vibrant orange spectrum, embodying the company’s bold vision.
“Syneos Health fully expresses our value proposition – that is, our ability to deliver integrated end-to-end solutions and create new paths for our customers to develop and commercialize their therapies,” said
The company’s highly integrated platform leverages a powerful combination of clinical and commercial solutions. For example, behavioral insights are leveraged to accelerate clinical trial recruitment, and therapeutic know-how infuses multi-channel commercial programs to better engage increasingly hard-to-reach stakeholders. All of these solutions are designed to improve the likelihood of launch success.
Macdonald continued, “As commercialization experts, we understand the importance a strong brand plays in creating differentiation, conversion and loyalty. Our new identity reinforces our fully integrated business model, positions
In connection with the name change,
To Connect with Syneos:
- Learn more about how we are shortening the distance from lab to life at syneoshealth.com
- See how biopharmaceutical acceleration can work for you by viewing our video
- Hear perspectives from our clinical and commercial experts on current challenges and considerations for bringing a product to market by subscribing to our podcast
- Gain additional insight into our thought leadership, events and company news by engaging with us on LinkedIn, Twitter and
Cautionary Statement Regarding Forward-Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include, but are not limited to: risks associated with the integration of our business with the business of inVentiv, and our operation of the combined business following the closing of the Merger; our ability to maintain or generate new business awards; our ability to increase our market share, grow our business and execute our growth strategies; our backlog not being indicative of future revenues and our ability to realize the anticipated future revenue reflected in our backlog; our ability to adequately price our contracts and not overrun cost estimates; general and international economic, political and other risks, including currency and stock market fluctuations and the uncertain economic environment; fluctuations in our financial results; reliance on key personnel; our customer or therapeutic area concentration; and the other risk factors set forth in our Form-Q for the quarter ended
Vice President, Investor Relations
+1 919 745 2745
+1 202 210 5992
Source: INC Research, LLC